跳至主要内容
临床试验/ACTRN12609000528257
ACTRN12609000528257已完成3 期

The impact of oxytocin in Schizophrenia to treat social communication problems.

niversity of Sydney0 个研究点目标入组 40 人开始时间: 2009年7月2日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 65 Years(—)
性别
Male

入选标准

  • Adult males with a primary diagnosis of schizophrenia as determined by interview on the Diagnostic INterview for Psychoses (DIP) and symptoms as assessed by the Positive and Negative Syndrome Scale (PANSS)

排除标准

  • Participants will be excluded if they meet Diagnostic and Statistical Manual
  • of Mental Disorders (DSM-IV) criteria for current alcohol or substance dependence (other than nicotine) within the last 6 months, have medical conditions that preclude participation in drug trials (including significant brain, cardiac, liver, lung, endocrinological or metabolic disorders) and if their Intelligence Quotient (IQ) falls below 75. Participants must be stabilised on medication for a period of 8 weeks. No females are included in this study.

研究者

相似试验